Premium
Activity‐Directed Synthesis of Inhibitors of the p53/ h DM2 Protein–Protein Interaction
Author(s) -
Green Adam I.,
Hobor Fruzsina,
Tinworth Christopher P.,
Warriner Stuart,
Wilson Andrew J.,
Nelson Adam
Publication year - 2020
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202002153
Subject(s) - drug discovery , computational biology , small molecule , function (biology) , identification (biology) , ligand (biochemistry) , protein–protein interaction , protein function , ligand efficiency , chemistry , combinatorial chemistry , biology , biochemistry , microbiology and biotechnology , receptor , gene , botany
Protein–protein interactions (PPIs) provide a rich source of potential targets for drug discovery and biomedical science research. However, the identification of structural‐diverse starting points for discovery of PPI inhibitors remains a significant challenge. Activity‐directed synthesis (ADS), a function‐driven discovery approach, was harnessed in the discovery of the p53/ h DM2 PPI. Over two rounds of ADS, 346 microscale reactions were performed, with prioritisation on the basis of the activity of the resulting product mixtures. Four distinct and novel series of PPI inhibitors were discovered that, through biophysical characterisation, were shown to have promising ligand efficiencies. It was thus shown that ADS can facilitate ligand discovery for a target that does not have a defined small‐molecule binding site, and can provide distinctive starting points for the discovery of PPI inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom